Australia’s GBMA Working To Address Coronavirus Risks
Consumers Urged Not To ‘Panic Purchase’ And Stockpile Drugs
Executive Summary
Australia’s GBMA off-patent industry association says its members are working to minimize the effects of coronavirus, amid reports of drug shortages and empty pharmacy shelves.
You may also be interested in...
Australia Relaxes Competition Rules To Facilitate Coronavirus Response
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.
Aspen Expects Growth Following Sandoz And Viatris Deals
Aspen expects to report significant growth in its continuing operations for the first half of its financial year, following deals with Sandoz and Viatris that have seen the South African firm divest major businesses in Japan and Europe.
Three Pillars Must Support Value Added Medicines In EU
Medicines for Europe has called for fresh efforts to bolster the value added medicines sector and “level the playing field” with the US and its 505(b)(2) pathway, launching a new report setting out the three key areas in which greater EU action is needed.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: